Tenapanor Hydrochloride: A Comprehensive Monograph on a First-in-Class NHE3 Inhibitor for Gastrointestinal and Renal Disorders

Executive Summary

Tenapanor Hydrochloride is a first-in-class, minimally absorbed, small-molecule inhibitor of the intestinal Sodium/Hydrogen Exchanger 3 (NHE3).[1] This novel agent acts locally within the gastrointestinal tract to exert its therapeutic effects, representing a significant innovation in the management of distinct disorders in gastroenterology and nephrology. It is commercially available under two brand names, each targeting a separate indication:

Ibsrela for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults, and Xphozah for the reduction of serum phosphorus in adults with Chronic Kidney Disease (CKD) on dialysis.[2]

The singular mechanism of NHE3 inhibition produces two distinct pharmacodynamic outcomes. For IBS-C, Tenapanor functions as a "retainagogue," reducing sodium absorption from the gut, which leads to an osmotic retention of water in the intestinal lumen. This action increases stool water content, softens stool consistency, and accelerates colonic transit, thereby alleviating the primary symptoms of constipation and abdominal pain associated with IBS-C.[5] For hyperphosphatemia in CKD, Tenapanor acts as a novel phosphate absorption inhibitor. Its inhibition of NHE3 is understood to induce conformational changes in intestinal tight junctions, reducing paracellular permeability specifically to phosphate and thereby decreasing its absorption from the diet. This mechanism is fundamentally different from traditional phosphate binders, which sequester phosphate within the gut lumen.[1]

The clinical efficacy of Tenapanor has been established in a robust program of Phase 3 clinical trials. For the IBS-C indication, the T3MPO-1 and T3MPO-2 trials demonstrated that Ibsrela produced statistically significant improvements in the composite primary endpoint of reduced abdominal pain and increased complete spontaneous bowel movements compared to placebo.[9] For the hyperphosphatemia indication, the PHREEDOM, AMPLIFY, and NORMALIZE trials collectively established the efficacy of Xphozah as both a monotherapy and an add-on therapy to phosphate binders, showing significant reductions in serum phosphorus levels and enabling a greater proportion of patients to achieve target concentrations.[10]

The safety profile of Tenapanor is defined by its local action and minimal systemic exposure. The most significant safety concern, highlighted by a U.S. Food and Drug Administration (FDA) Black Box Warning, is the risk of serious dehydration in pediatric patients, leading to a contraindication in children under 6 years of age.[3] In adults, the most frequently reported adverse event is diarrhea, a direct consequence of the drug's mechanism of action. While typically mild to moderate, diarrhea can be severe and is the primary reason for treatment discontinuation.[9]

In summary, Tenapanor Hydrochloride is a unique therapeutic agent whose novel mechanism provides a new approach for two challenging conditions. It offers an important alternative for adults with IBS-C and presents a new paradigm for managing hyperphosphatemia in CKD patients on dialysis, particularly those who are intolerant of or inadequately managed by traditional phosphate binders. Its successful clinical application depends on careful patient selection and proactive management of its predictable gastrointestinal side effects.

Tenapanor Hydrochloride: Profile of a Novel Therapeutic Agent

Tenapanor Hydrochloride is a pioneering therapeutic agent, distinguished by its novel mechanism of action and its dual application in disparate medical fields. Its development marks a significant advancement, offering a new pharmacological approach for conditions where existing treatments have limitations.

Chemical and Physical Properties

Tenapanor Hydrochloride is a complex small molecule with the chemical formula C50​H68​Cl6​N8​O10​S2​ and a molecular weight of 1217.96 Daltons.[16] Its structure is integral to its function, particularly its pharmacokinetic profile. The molecule has a very low water solubility of 0.00292 mg/mL, a property that is fundamental to its design as a locally acting agent with minimal systemic absorption.[16] This characteristic ensures that the drug remains predominantly within the gastrointestinal lumen to exert its effects directly on the intestinal epithelium, thereby limiting systemic exposure and associated off-target effects.

Therapeutic Classification

Tenapanor's classification is multifaceted, reflecting its unique mechanism and its two distinct therapeutic roles.

Primary Class: Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor

At its core, Tenapanor is a first-in-class inhibitor of the Sodium/Hydrogen Exchanger 3, or NHE3.[1] NHE3 is an antiporter protein located on the apical membrane of epithelial cells lining the small intestine and colon. It is the primary transporter responsible for the absorption of dietary sodium.[1] By selectively inhibiting NHE3, Tenapanor fundamentally alters sodium and fluid balance within the gut, which is the basis for all its clinical effects. The FDA considers it to be a first-in-class medication for this reason.[2]

Indication-Specific Classes

The downstream consequences of NHE3 inhibition lead to two distinct therapeutic classifications:

• For Irritable Bowel Syndrome with Constipation (IBS-C): "Retainagogue" In the context of IBS-C, Tenapanor is described as a "retainagogue".6 This term was introduced to differentiate its mechanism from other classes of drugs used for constipation. Unlike secretagogues (e.g., lubiprostone) or guanylate cyclase-C (GC-C) agonists (e.g., linaclotide, plecanatide), which actively promote the secretion of chloride, bicarbonate, and water into the intestinal lumen, Tenapanor works by preventing the absorption of sodium that is already present. This inhibition of sodium uptake causes water to be osmotically retained in the lumen, rather than actively secreted into it.[6] This distinction is pharmacologically significant and positions Tenapanor in a unique category for the treatment of IBS-C.
• For Hyperphosphatemia in Chronic Kidney Disease (CKD): Non-Binder Phosphate Absorption Inhibitor For its renal indication, Tenapanor is classified as a first-in-class, non-binder phosphate absorption inhibitor.1 This classification highlights its radical departure from all other available therapies for hyperphosphatemia. Conventional treatments, such as sevelamer, lanthanum, or calcium-based binders, work by physically binding to dietary phosphate in the gut to form insoluble complexes that are then excreted.1 Tenapanor does not bind phosphate. Instead, it reduces phosphate absorption by modulating the permeability of the paracellular pathway—the space between intestinal cells.1

Commercial Formulations and Branding

The dual applications of Tenapanor are reflected in a deliberate and strategic approach to its branding and formulation, which is directly tied to the drug's pharmacological profile.

• Ibsrela®: Marketed for the treatment of IBS-C in adults, Ibsrela is supplied as a 50 mg oral tablet.[2]
• Xphozah®: Marketed for the reduction of serum phosphorus in adults with CKD on dialysis, Xphozah is supplied in lower, titratable strengths of 10 mg, 20 mg, and 30 mg oral tablets.[2]

The use of two distinct brand names and non-overlapping dosage strengths for the same active ingredient is a clear reflection of the therapeutic paradox inherent in Tenapanor's mechanism. The primary effect of NHE3 inhibition is an increase in intestinal fluid and motility. For IBS-C, this effect is the desired therapeutic outcome, aimed at relieving constipation. A consistent and robust effect is needed, which justifies the higher, fixed 50 mg dose of Ibsrela.

Conversely, for patients with CKD on dialysis being treated for hyperphosphatemia, this same pharmacological effect manifests as the primary and most significant adverse event: diarrhea.[15] This patient population is particularly vulnerable to the consequences of fluid shifts and dehydration. Therefore, the lower and titratable dosing regimen for Xphozah is a critical risk-mitigation strategy. It allows clinicians to carefully balance the desired phosphate-lowering effect against the gastrointestinal tolerability for each individual patient, optimizing the benefit-risk ratio.[20] The separate branding further serves to prevent prescribing errors and clearly demarcates the distinct therapeutic goals and safety considerations for gastroenterologists and nephrologists, respectively. This demonstrates how a deep understanding of a drug's pharmacology informs not only its clinical application but also its entire commercial and regulatory strategy.

A Dual-Pronged Mechanism of Action

The therapeutic utility of Tenapanor in two seemingly unrelated conditions—IBS-C and hyperphosphatemia—stems from a single, targeted molecular action: the inhibition of the intestinal Sodium/Hydrogen Exchanger 3 (NHE3). The downstream effects of this singular action diverge to address the distinct pathophysiology of each disorder.

Core Mechanism: Selective Inhibition of Intestinal NHE3

Tenapanor is a potent, selective, and locally acting inhibitor of the NHE3 antiporter.[1] NHE3 is densely expressed on the apical (luminal) surface of epithelial cells throughout the small intestine and colon.[1] Its physiological function is to facilitate the exchange of one extracellular (luminal) sodium ion (

Na+) for one intracellular proton (H+), a process that is central to the absorption of dietary sodium and the maintenance of fluid homeostasis in the gut.[1]

By binding to and inhibiting NHE3, Tenapanor effectively blocks this exchange. This action reduces the primary pathway for sodium absorption from the gastrointestinal tract, leading to a net increase in the concentration of sodium ions within the intestinal lumen.[1] Because Tenapanor is minimally absorbed, its action is confined to the gut, preventing systemic effects on sodium handling, such as those that might occur in the kidney.[2]

Pharmacodynamic Effect in IBS-C: The "Retainagogue" Model

The consequences of luminal sodium retention are central to Tenapanor's efficacy in IBS-C. Water movement across the intestinal epithelium follows osmotic gradients. By increasing the concentration of sodium solutes in the lumen, Tenapanor creates an osmotic force that pulls water into the gut and, more importantly, prevents water that is already there from being reabsorbed.[1] This mechanism of action is termed the "retainagogue" effect, as it causes water to be retained within the intestine.[6]

This influx and retention of water leads to a significant increase in the net fluid volume of the stool. The clinical results are twofold:

1. Softer Stool Consistency: The increased water content softens hard, constipated stools, making them easier to pass.[1]
2. Accelerated Intestinal Transit: The increased luminal volume stimulates colonic motility and accelerates transit time, leading to more frequent bowel movements.[1]

Together, these effects directly address the constipation component of IBS-C. Furthermore, preclinical data from animal models suggest that Tenapanor may also address the abdominal pain component of IBS-C through additional mechanisms, including decreasing visceral hypersensitivity and reducing intestinal permeability.[6] While the direct relevance of these findings to humans has not been definitively established, they provide a plausible biological basis for the observed reductions in abdominal pain in clinical trials.[6]

Pharmacodynamic Effect in Hyperphosphatemia: Paracellular Pathway Modulation

Tenapanor's mechanism for lowering serum phosphorus is more intricate and represents a paradigm shift in the management of hyperphosphatemia. It is crucial to reiterate that Tenapanor is not a phosphate binder.[1] Its action is indirect and relies on altering the physical properties of the intestinal barrier.

Dietary phosphate is absorbed through two main routes: a transcellular pathway (through the cells), which is active and saturable, and a paracellular pathway (between the cells), which is passive and concentration-dependent. The paracellular route is believed to be the primary pathway for phosphate absorption, especially under the high-phosphate dietary conditions common in patients with CKD.[1] This pathway is regulated by a complex of proteins known as tight junctions, which form a selectively permeable seal between adjacent epithelial cells.

The inhibition of NHE3 by Tenapanor leads to a transient increase in the concentration of intracellular protons within the enterocytes. It is hypothesized that this change in intracellular pH triggers a signaling cascade that results in a conformational change of the tight junction proteins.[1] This change effectively "tightens" the junctions, increasing the transepithelial electrical resistance and specifically reducing the permeability of the paracellular pathway to phosphate ions.[1] By blocking this primary, passive route of absorption, Tenapanor significantly reduces the amount of dietary phosphate that enters the bloodstream.[1]

The efficacy of Tenapanor for both of its indications is intrinsically linked to the composition of the intestinal lumen at the time of administration. The drug's local action is dependent on the presence of its targets—dietary sodium for the IBS-C effect and dietary phosphate for the CKD effect. This dependency explains the consistent and critical administration instruction across both formulations to take the drug immediately before a meal.[3] Pharmacodynamic studies have confirmed this relationship, demonstrating that administering Tenapanor 5 to 10 minutes before a meal maximizes the 24-hour excretion of both sodium and phosphorus in the stool when compared to administration in a fasted state or after a meal.[20] This underscores that patient adherence to the pre-meal dosing schedule is not merely a recommendation for convenience but is a fundamental requirement for achieving the drug's intended therapeutic effect. For a patient with IBS-C, taking the drug without a sodium-containing meal would likely blunt its laxative properties. Similarly, for a CKD patient, taking the drug without a phosphate-containing meal would render that dose largely ineffective for controlling serum phosphorus. This creates a significant need for patient education, as the drug's clinical efficacy is directly coupled with a behavioral component in a manner that is distinct from most systemically absorbed medications.

Pharmacokinetic and Pharmacodynamic Profile: Local Action, Minimal Exposure

The pharmacokinetic profile of Tenapanor is a defining feature of the drug and is central to its mechanism of action and safety profile. It is designed to act locally within the gastrointestinal tract with very limited entry into the systemic circulation. This profile of Absorption, Distribution, Metabolism, and Excretion (ADME) has been characterized in multiple studies.

Absorption

Tenapanor exhibits minimal systemic absorption following oral administration. This is a deliberate design feature that confines its pharmacological activity to the gut. In clinical pharmacokinetic studies involving healthy subjects, plasma concentrations of the parent drug, Tenapanor, were consistently below the lower limit of quantitation (LLOQ), which is typically less than 0.5 nanograms per milliliter (ng/mL), even after repeated twice-daily dosing.[14] Because of these unquantifiable levels, standard pharmacokinetic parameters for the parent drug, such as area under the curve (AUC), maximum concentration (

Cmax​), and half-life (t1/2​), could not be calculated.[3] This minimal absorption is the cornerstone of its favorable systemic safety profile, as it drastically reduces the potential for off-target adverse effects in other organ systems.[1]

Distribution

Due to the negligible systemic absorption of the parent drug, its distribution characteristics in the body are not well defined. However, in vitro studies have provided insight into its potential behavior if it were to enter the circulation. These studies show that both Tenapanor and its primary metabolite, M1, are highly bound to plasma proteins. The protein binding is approximately 99% for Tenapanor and 97% for its M1 metabolite.[20] This high degree of protein binding would further limit the amount of free, active drug available to interact with systemic tissues.

Metabolism

Tenapanor is metabolized primarily by the Cytochrome P450 (CYP) enzyme system, specifically by the CYP3A4 and CYP3A5 isoforms.[20] Given that the drug is poorly absorbed from the gut, this metabolism is thought to occur predominantly within the intestinal enterocytes (first-pass metabolism) rather than systemically in the liver.[24]

This metabolic process yields a major metabolite, designated M1 (also known as AZ13792925), which is pharmacologically inactive against the NHE3 transporter.[26] Unlike the parent drug, the M1 metabolite is absorbed to a sufficient degree to be quantifiable in the plasma. Following a 50 mg twice-daily regimen, the M1 metabolite reaches a steady-state maximum concentration (

Cmax​) of approximately 13 to 15 ng/mL.[20] It appears slowly in the plasma, with the time to reach maximum concentration (

Tmax​) being between 7 and 8 hours after a single dose.[26] The exposure to this inactive metabolite has been found to be generally similar between Chinese and Caucasian subjects.[26]

Excretion

The primary route of elimination for Tenapanor and its metabolites is through the feces, consistent with its poor absorption. In a human radiolabeled study, approximately 79% of the administered radioactive dose was recovered in the feces within 240 hours. A substantial portion of this, accounting for 65% of the total dose, was excreted as unchanged parent drug, confirming that the majority of the ingested medication passes through the gastrointestinal tract intact.[20]

A minor fraction of the dose, approximately 9%, was recovered in the urine, almost entirely in the form of metabolites.[20] The major metabolite, M1, is excreted unchanged in the urine and accounts for about 1.5% of the total administered dose.[20] Pharmacokinetic analysis of M1 revealed a long elimination half-life, ranging from 16 to 21 hours, with steady-state concentrations being achieved within 4 to 5 days of continuous dosing.[26]

Pharmacodynamics

The pharmacodynamic effects of Tenapanor are directly linked to its local action in the gut and are highly dependent on the timing of administration relative to meals. As previously discussed, clinical studies have conclusively shown that administering Tenapanor 5 to 10 minutes before a meal significantly increases the 24-hour excretion of both sodium and phosphorus in the stool compared to taking the drug in a fasted state.[20] This confirms that the drug's efficacy is maximized when it is present in the gut lumen concurrently with a meal, allowing it to inhibit the absorption of dietary sodium and phosphate most effectively. Studies in healthy volunteers have corroborated these findings, demonstrating that Tenapanor treatment leads to a measurable increase in stool sodium and phosphorus content, accompanied by a corresponding decrease in the urinary excretion of these electrolytes.[31]

Clinical Efficacy in Irritable Bowel Syndrome with Constipation (IBS-C)

The approval of Tenapanor (marketed as Ibsrela) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults was based on a robust clinical development program, highlighted by two large, pivotal Phase 3 trials. These studies were designed to rigorously evaluate the efficacy and safety of Tenapanor in a well-defined patient population suffering from this burdensome condition.

Pivotal Phase 3 Program: T3MPO-1 and T3MPO-2

The efficacy of Ibsrela was established in two randomized, double-blind, placebo-controlled, multicenter trials: T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138).[3] The designs of these trials were identical for the first 12 weeks of treatment. T3MPO-1 included a 4-week randomized withdrawal period after the initial 12 weeks, while T3MPO-2 continued as a double-blind treatment for a total of 26 weeks, providing longer-term efficacy and safety data.[9]

Patient Population

The trials enrolled adult patients who met the Rome III diagnostic criteria for IBS-C. To ensure a study population with significant and active symptoms, all participants were required to meet specific criteria during a 2-week baseline run-in period. These criteria included having, on average, fewer than 3 complete spontaneous bowel movements (CSBMs) per week and a mean worst abdominal pain score of at least 3 on a 0-to-10-point numeric rating scale.[3] The study population was representative of typical IBS-C patients, with a mean age of 46 years and predominantly female (80%) participants.[3]

Primary Efficacy Endpoint

The primary endpoint for both trials was a composite responder analysis, as defined by the FDA, assessed over the initial 12-week treatment period. A patient was classified as a "responder" if they met both of the following criteria in the same week for at least 6 of the 12 weeks of treatment [3]:

1. Abdominal Pain Responder: A reduction of at least 30% from baseline in the weekly average of their worst daily abdominal pain score.
2. CSBM Responder: An increase of at least 1 CSBM from their baseline weekly average.

This composite endpoint is a stringent measure, as it requires concurrent improvement in both the pain and constipation symptoms of IBS-C to be considered a treatment success.

Efficacy Results

In both pivotal trials, Tenapanor administered at a dose of 50 mg twice daily demonstrated a statistically significant improvement over placebo in the primary composite endpoint. The results, summarized in Table 1 below, confirmed the drug's efficacy in providing comprehensive relief of IBS-C symptoms.[9]

In addition to meeting the primary endpoint, Tenapanor also showed significant improvements in the individual components of pain and constipation. A key finding from both trials was the rapid onset of action, with improvements from baseline in both average weekly CSBMs and abdominal pain scores observed as early as the first week of treatment. This improvement was then maintained throughout the entire treatment period.[3] The 26-week data from the T3MPO-2 trial further supported the durability of this effect over longer-term use.[9]

Long-Term Safety and Other Studies

The long-term safety profile of Tenapanor in the IBS-C population was further evaluated in the T3MPO-3 study (NCT02727751). This was a Phase 3, open-label study that enrolled patients who had completed either the T3MPO-1 or T3MPO-2 trial, following them for a total treatment duration of approximately 52 to 55 weeks.[33] This study provided crucial data confirming the long-term tolerability of the 50 mg twice-daily dose.

Furthermore, ongoing research continues to explore the broader effects of Tenapanor. One study, for instance, is investigating how the administration of Tenapanor impacts the gut microbiome of patients with IBS-C.[34] Such research may provide deeper understanding into the variability of patient responses and could potentially identify biomarkers to predict treatment success in the future.

Table 1: Summary of Primary Efficacy Endpoints in Pivotal IBS-C Trials (T3MPO-1 & T3MPO-2)
Trial Identifier	Treatment Group	N (Patients)	Primary Endpoint Responder Rate (%)	Placebo Responder Rate (%)	Absolute Difference (%) [95% CI]	p-value
T3MPO-1 (12 Weeks)	Tenapanor 50 mg BID	307	27%	19%	8% [2%, 15%]	0.02
T3MPO-2 (12 Weeks)	Tenapanor 50 mg BID	293	37%	24%	13% [6%, 20%]	<0.001
Data sourced from 3, and.9

Clinical Efficacy in Hyperphosphatemia in Chronic Kidney Disease (CKD)

The approval of Tenapanor (marketed as Xphozah) for the control of serum phosphorus in adults with CKD on dialysis was supported by a comprehensive and multi-faceted Phase 3 clinical trial program. This program was designed to evaluate the drug's efficacy and safety in various clinical scenarios, including as a monotherapy, as an add-on to existing treatments, and for long-term maintenance of normal phosphorus levels. This robust body of evidence was essential for establishing its role in the management of hyperphosphatemia, a persistent and challenging complication of advanced kidney disease.

The PHREEDOM Trial (NCT03427125): Efficacy as Monotherapy

The PHREEDOM study was a pivotal, long-term trial designed to assess the efficacy of Tenapanor as a standalone therapy for hyperphosphatemia.[10]

Design

The trial featured a sophisticated, multi-part design. It began with a 26-week, open-label, randomized treatment period where patients received either Tenapanor or an active safety control (sevelamer carbonate). This was followed by a 12-week, double-blind, placebo-controlled, randomized withdrawal period (RWP) for patients who had responded to Tenapanor. The trial concluded with a 14-week open-label safety extension.[10]

Primary Efficacy Endpoint

The primary endpoint was specifically designed to demonstrate the durable effect of Tenapanor. It was defined as the difference in the change in serum phosphorus (sP) from the end of the 26-week treatment period to the end of the 12-week RWP, comparing patients who continued on Tenapanor to those who were withdrawn to placebo.[10] This design effectively isolates the drug's effect by showing what happens when it is removed.

Results

The PHREEDOM trial successfully met its primary endpoint. During the initial 26-week open-label treatment period, patients treated with Tenapanor monotherapy experienced a clinically and statistically significant reduction in their sP levels. On average, 77% of patients in the intent-to-treat population had a mean sP reduction of 2.0 mg/dL from baseline.[15] In the subsequent randomized withdrawal period, patients who continued on Tenapanor maintained this control, while those who were switched to placebo experienced a rapid and significant increase in their sP levels. The least-squares mean difference in sP change between the Tenapanor and placebo groups during the RWP was -1.4 mg/dL (

p<0.0001), unequivocally demonstrating that Tenapanor was responsible for maintaining phosphorus control.[10]

The AMPLIFY Trial (NCT03824587): Efficacy as Add-on Therapy

The AMPLIFY study was designed to evaluate Tenapanor's efficacy in a more challenging, real-world scenario: patients who remained hyperphosphatemic despite being on stable doses of traditional phosphate binders.[11]

Design

This was a 4-week, randomized, double-blind, placebo-controlled trial. Eligible patients had a serum phosphorus level of ≥5.5 mg/dL and ≤10.0 mg/dL while on a stable phosphate binder regimen. Patients were randomized to receive either Tenapanor or placebo, in addition to their ongoing binder therapy.[11]

Primary Efficacy Endpoint

The primary endpoint was the change in serum phosphorus concentration from baseline to the end of the 4-week treatment period, comparing the group receiving Tenapanor plus binders to the group receiving placebo plus binders.[11]

Results

The AMPLIFY trial also met its primary endpoint with high statistical significance. The addition of Tenapanor to existing phosphate binder therapy resulted in a significantly greater reduction in serum phosphorus compared to binders alone. The mean change in sP from baseline to week 4 was -0.84 mg/dL in the Tenapanor add-on group, compared to -0.19 mg/dL in the placebo add-on group, resulting in a treatment difference of -0.7 mg/dL (p=0.0004).[11] Furthermore, a key secondary endpoint demonstrated that this dual-mechanism approach enabled approximately twice as many patients to achieve the clinically recommended serum phosphorus target of less than 5.5 mg/dL compared to those on binders alone (43% vs. 22% at week 1,

p<0.001; 37% vs. 22% at week 4, p=0.01).[11]

The NORMALIZE Study (NCT03988920): Long-Term Efficacy in Achieving Normal Phosphorus Levels

The NORMALIZE study was a long-term, open-label extension trial for patients who completed the PHREEDOM study. Its primary objective was to evaluate the ability of Tenapanor, used as a foundational therapy either alone or in combination with the phosphate binder sevelamer, to achieve and maintain serum phosphorus levels within the normal physiological range (2.5–4.5 mg/dL) over an extended period of up to 18 months.[12]

Results

The NORMALIZE study demonstrated the potential for long-term, durable control of hyperphosphatemia with a Tenapanor-based regimen. At the end of the study, 33% of all patients in the full analysis set achieved a normal serum phosphorus level between 2.5 and 4.5 mg/dL.[12] An earlier interim analysis of 171 patients treated for up to 9 months found that up to 47.4% achieved a serum phosphorus level of less than 4.6 mg/dL, representing a 58% improvement over the rates typically seen with the standard of care (phosphate binders alone) as reported in the Dialysis Outcomes Practice Patterns Study (DOPPS).[42] The study confirmed that Tenapanor, either as monotherapy or in combination with a reduced burden of phosphate binders, can help a significant portion of patients on maintenance dialysis achieve normal serum phosphorus concentrations, a goal that has been historically difficult to attain.[12]

Table 2: Comparative Analysis of Primary Endpoints in Pivotal Hyperphosphatemia Trials
Trial Name	Study Design	Patient Population	Primary Endpoint	Key Efficacy Result
PHREEDOM	26-week open-label treatment followed by a 12-week randomized withdrawal period (RWP)	CKD patients on dialysis (Monotherapy)	Difference in sP change between Tenapanor and placebo during the RWP	LS Mean Difference = -1.4 mg/dL (p<0.0001) in favor of Tenapanor
AMPLIFY	4-week, randomized, placebo-controlled trial	CKD patients on dialysis with uncontrolled sP despite stable binder therapy (Add-on Therapy)	Change in sP from baseline to week 4	Mean sP reduction was 0.7 mg/dL greater with Tenapanor + binder vs. placebo + binder (p=0.0004)
NORMALIZE	Up to 18-month open-label extension study	CKD patients on dialysis who completed PHREEDOM (Long-term Goal Achievement)	Evaluate ability to achieve normal sP (2.5-4.5 mg/dL)	At study end, 33% of patients achieved a normal sP level.
Data sourced from.10

Comprehensive Safety and Tolerability Profile

The safety profile of Tenapanor is well-characterized and is intrinsically linked to its mechanism of action as a locally acting NHE3 inhibitor with minimal systemic absorption. The most significant safety considerations revolve around its potent effects on gastrointestinal fluid balance, leading to a critical warning for pediatric use and a high incidence of diarrhea in adults.

Black Box Warning: Risk of Serious Dehydration in Pediatric Patients

The U.S. Food and Drug Administration has mandated a boxed warning, its most stringent safety alert, for Tenapanor regarding the risk of serious dehydration in pediatric patients.[3] This warning is based on compelling nonclinical data and has led to specific contraindications and precautions for its use in younger populations.

• Contraindication (Absolute): Tenapanor is strictly contraindicated in patients less than 6 years of age.[3]
• Warning and Avoidance: The use of Tenapanor should be avoided in patients aged 6 years to less than 12 years of age.[3]
• Lack of Data: The safety and effectiveness of Tenapanor have not been established in any pediatric patient under the age of 18.[3]

The basis for this strong warning comes from toxicology studies conducted in juvenile rats. In very young rats, whose age is approximately equivalent to a human age of less than 2 years, the administration of Tenapanor resulted in significant morbidity and mortality. These deaths were presumed to be a direct consequence of severe diarrhea leading to profound dehydration.[3] Because no safety data are available from studies in older juvenile rats (equivalent to human ages 2 to <12 years), a precautionary approach of avoiding use in this age group has been adopted.[14] The clinical implication of this warning is paramount: accidental ingestion of Tenapanor by a young child could constitute a medical emergency. This necessitates explicit and repeated counseling for adult patients on the importance of storing the medication securely and keeping it out of the reach of children at all times.[13]

Other Contraindications

In addition to the pediatric contraindication, Tenapanor is also contraindicated in adult patients with a known or suspected mechanical gastrointestinal obstruction.[3] The drug's mechanism increases intestinal fluid and promotes motility; in the presence of a physical blockage, this could lead to a dangerous increase in intraluminal pressure, potentially causing bowel perforation or other serious complications.

Adverse Events Profile in Adults

The adverse event profile in adults is dominated by gastrointestinal effects that are a direct extension of the drug's intended pharmacology.

Diarrhea

Diarrhea is, by a significant margin, the most common adverse event reported with Tenapanor use across all clinical trials and for both approved indications.[5]

• Incidence: The rate of diarrhea is indication-dependent, reflecting the different dosing and patient populations.
• In IBS-C trials, the incidence was approximately 15-16% in patients treated with Tenapanor, compared to 2-4% in the placebo group.[9]
• In CKD trials for hyperphosphatemia, the incidence was considerably higher, ranging from 43% to 53%.[15] This higher rate is likely due to a combination of factors, including the underlying gastrointestinal dysmotility common in CKD and the different therapeutic goal (where looser stools are a side effect, not an endpoint).
• Severity and Management: Most cases of diarrhea are reported as mild to moderate in severity and are often transient, occurring within the first few days of treatment initiation.[15] However, severe diarrhea was reported in approximately 2.5% of IBS-C patients.[6] The recommended management for severe diarrhea is to suspend dosing immediately and ensure the patient is adequately rehydrated.[6]
• Discontinuation: Diarrhea is also the most common adverse reaction leading to treatment discontinuation. Discontinuation rates were approximately 6.5% in the IBS-C trials and as high as 16% in the long-term PHREEDOM trial for CKD.[9]

Other Common Adverse Effects

Other adverse effects reported in at least 2% of patients and at a higher rate than placebo include abdominal distension, flatulence (gas), and dizziness.[3]

Use in Specific Populations

• Pregnancy and Lactation: Tenapanor is minimally absorbed from the gastrointestinal tract, and plasma concentrations of the parent drug are generally undetectable. Consequently, maternal use is not expected to result in any significant fetal or infant exposure to the drug. The available human data, though limited, have not identified any drug-associated risks for major birth defects, miscarriage, or other adverse outcomes.[13]
• Renal Impairment: In the IBS-C clinical trials, an analysis of a subgroup of patients with baseline renal impairment (defined as an estimated glomerular filtration rate of less than 90 mL/min/1.73m²) was conducted. This analysis revealed that patients with renal impairment treated with Tenapanor had a higher incidence of diarrhea (20%) compared to patients with normal renal function (13%).[13] No other differences in the safety profile were noted in this subgroup.
• Hepatic Impairment: A dedicated pharmacokinetic study was conducted in patients with moderate hepatic impairment (Child-Pugh Class B). As in healthy subjects, plasma concentrations of Tenapanor were mostly below the limit of quantitation. The systemic exposure to the inactive M1 metabolite was slightly lower in this population, but the difference was not considered clinically relevant. Therefore, no dose adjustment is required for patients with hepatic impairment.[3]

Clinical Application: Dosage, Administration, and Drug Interactions

The effective and safe use of Tenapanor in clinical practice requires a clear understanding of its indication-specific dosing, precise administration instructions, and its unique drug interaction profile, which is driven by its local action within the gastrointestinal tract.

Indication-Specific Dosing

The recommended dosage of Tenapanor differs significantly between its two approved indications, a strategy designed to optimize the risk-benefit profile for each distinct patient population.

• For Irritable Bowel Syndrome with Constipation (IBS-C) - Ibsrela: The recommended dosage for adults is a fixed dose of 50 mg taken orally, twice daily.[3] This higher dose is intended to produce a consistent and robust effect on intestinal fluid and motility to relieve symptoms.
• For Hyperphosphatemia in Chronic Kidney Disease (CKD) - Xphozah: The recommended starting dosage for adults is 30 mg taken orally, twice daily. The dosage can be adjusted as needed based on serum phosphorus levels and, importantly, to manage gastrointestinal tolerability, particularly diarrhea.[20] The availability of 10 mg and 20 mg tablets facilitates this titration.

Administration Instructions

Proper administration is critical to maximizing the efficacy of Tenapanor.

• Timing with Meals: For both indications, Tenapanor tablets should be taken immediately prior to the morning and evening meals (or the first and last meals of the day).[3] This timing ensures that the drug is present in the gut lumen to inhibit the absorption of sodium and phosphate from the ingested meal.
• Missed Doses: If a patient misses a dose, they should be instructed to skip the missed dose and take the next dose at its regularly scheduled time. Patients should not take two doses at the same time to make up for a missed one.[3]
• Special Instructions for Dialysis Patients: For patients with CKD on dialysis, Xphozah should not be administered immediately before a hemodialysis session. Instead, it should be taken immediately before the next meal following the dialysis session. This precaution is intended to mitigate the risk of patients experiencing diarrhea and potential fluid shifts during the hemodialysis procedure itself.[20]

Management of Drug-Drug Interactions

The drug interaction profile of Tenapanor is unique. Because it is minimally absorbed, it does not engage in typical systemic drug-drug interactions involving hepatic CYP enzymes. Instead, its interactions are localized to the gastrointestinal tract and are primarily related to its effects on intestinal transporters or direct physical binding.

The localized action of Tenapanor means its interaction profile is fundamentally different from systemically absorbed drugs. While it has a low potential to affect the systemic metabolism of other drugs, its high concentration within the gut lumen allows it to interfere with local processes. Tenapanor has been identified as an inhibitor of the intestinal uptake transporter OATP2B1 (Organic Anion-Transporting Polypeptide 2B1).[20] This inhibition can decrease the intestinal absorption of other drugs that are substrates for this transporter, leading to reduced systemic exposure and potentially diminished therapeutic efficacy. This mechanism explains the observed interactions with common medications like certain statins (atorvastatin, rosuvastatin) and the antihypertensive drug enalapril.[20] The clinical management for these interactions involves monitoring for a loss of efficacy of the co-administered drug and, if necessary, adjusting its dosage. For example, when co-administering with enalapril, blood pressure should be monitored, and the enalapril dose may need to be increased.[20]

A different type of interaction occurs with sodium polystyrene sulfonate (SPS), a potassium binder. This is a direct physical binding interaction within the gut, where SPS can bind to Tenapanor, preventing it from acting on NHE3.[20] The management for this is straightforward: a temporal separation of administration by at least 3 hours. This highlights a critical principle for minimally absorbed drugs: the assessment of drug-drug interactions must focus on local, intraluminal events in addition to systemic pharmacokinetics.

Table 3: Clinically Significant Drug Interactions and Management Recommendations
Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
OATP2B1 Substrates (e.g., atorvastatin, rosuvastatin, fluvastatin, enalapril, fexofenadine, bosentan, glyburide)	Inhibition of the intestinal uptake transporter OATP2B1 by Tenapanor.	Reduced absorption and systemic exposure of the OATP2B1 substrate, potentially leading to a loss of its therapeutic efficacy.	Monitor for signs of reduced efficacy of the co-administered drug. For enalapril, monitor blood pressure and increase the enalapril dose if needed. For other substrates, consider dose adjustments or alternative therapies based on clinical response.
Sodium Polystyrene Sulfonate (SPS)	Direct physical binding of Tenapanor by SPS within the gastrointestinal lumen.	Reduced availability of Tenapanor to inhibit NHE3, leading to decreased efficacy of Tenapanor.	Separate the administration of Tenapanor and SPS by at least 3 hours.
Data sourced from.20

Regulatory and Market Landscape

The regulatory journey of Tenapanor has been distinct for its two indications, reflecting the different clinical contexts and patient populations. Its approval status also varies between major global regulatory bodies.

U.S. Food and Drug Administration (FDA) Pathway

Tenapanor has received two separate marketing approvals from the U.S. FDA, under two different brand names.

Ibsrela (for IBS-C)

The New Drug Application (NDA) for Ibsrela for the treatment of IBS-C in adults was approved by the FDA on September 12, 2019.[2] Interestingly, the commercial launch of the product by the manufacturer, Ardelyx, Inc., was strategically delayed until

April 4, 2022.[32] This period between regulatory approval and market availability allowed the company to prepare for commercialization and pursue strategic collaborations.

Xphozah (for Hyperphosphatemia in CKD)

The regulatory pathway for Xphozah was significantly more complex and protracted. Following the submission of an NDA based on the positive results of the Phase 3 clinical program, Ardelyx received a Complete Response Letter (CRL) from the FDA in July 2021.[4] A CRL indicates that the agency has completed its review of an application but has decided that it cannot be approved in its present form. After a formal dispute resolution process and the resubmission of the NDA in April 2023, Xphozah was ultimately granted FDA approval on

October 17, 2023.[2]

The approved indication for Xphozah is specifically "to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy".[4] This specific labeling positions Xphozah as a second-line or combination therapy, reflecting the data from the AMPLIFY trial and the clinical need in patients who are not adequately managed by the current standard of care.

European Medicines Agency (EMA) Status

As of the latest available information, Tenapanor does not have a central marketing authorisation from the European Medicines Agency (EMA).[62] A search of the EMA's database of centrally authorized products does not list Tenapanor, Ibsrela, or Xphozah. While marketing authorisation in the European Union can also be obtained through national procedures in individual member states, there is no evidence in the provided materials to suggest this has occurred.[64]

However, a 2024 EMA document indicates a recent regulatory interaction. In June 2024, the EMA issued a positive decision on a "Product Specific Waiver" for Tenapanor.[67] This type of waiver relates to a Paediatric Investigation Plan (PIP), which is a development plan required by the EMA to ensure that necessary data on the use of a medicine in children are obtained. A positive decision on a PIP (or a waiver from its requirements) is a mandatory prerequisite before a company can submit a Marketing Authorisation Application (MAA) for a new medicine in the EU.

The absence of an EMA approval to date, despite approvals in the U.S. and Japan (where it is being developed by Ardelyx's partner, Kyowa Kirin [42]), could be attributable to several factors. Regulatory agencies in different regions can have varying requirements for clinical trial endpoints, different interpretations of the risk-benefit balance, or place different weight on specific safety signals. The high incidence of diarrhea, while considered manageable by the FDA, may have been a point of concern for European regulators. Alternatively, the lack of an EU approval could be the result of a strategic business decision by the manufacturer. Pursuing an MAA with the EMA is a resource-intensive process, and Ardelyx may have prioritized other markets or may be seeking a European commercial partner before proceeding. The recent positive PIP waiver decision, however, strongly suggests that the groundwork may be being laid for a future submission for marketing authorisation in the EU.

Synthesis and Concluding Remarks

Tenapanor Hydrochloride stands as a significant and genuine innovation in pharmacology, representing the first approved therapeutic agent that targets the intestinal Sodium/Hydrogen Exchanger 3. Its development and dual-indication approval underscore the potential of a single, highly specific molecular mechanism to address the pathophysiology of two distinct and challenging clinical conditions: Irritable Bowel Syndrome with Constipation and hyperphosphatemia in Chronic Kidney Disease.

The drug's profile is defined by a central therapeutic paradox: the same pharmacodynamic effect—the inhibition of sodium absorption and consequent retention of luminal fluid—serves as the primary therapeutic benefit in IBS-C while simultaneously constituting the primary dose-limiting adverse event, diarrhea, in the management of hyperphosphatemia. This duality is masterfully managed through a strategic approach to branding, dosing, and clinical positioning. The high, fixed dose of Ibsrela is designed to maximize the desired laxative effect in gastroenterology, whereas the lower, titratable dose of Xphozah allows nephrologists to carefully navigate the narrow therapeutic window between effective phosphate control and tolerable gastrointestinal side effects.

The clinical evidence supporting Tenapanor is robust. For IBS-C, it offers a novel "retainagogue" mechanism that provides statistically significant and clinically meaningful relief from the dual symptoms of constipation and abdominal pain. For patients with CKD on dialysis, it introduces an entirely new paradigm for phosphate management. By targeting the paracellular pathway of phosphate absorption, Xphozah offers a non-binder approach that can be used as monotherapy or, perhaps more importantly, as an add-on therapy to help the large proportion of patients who fail to reach their serum phosphorus goals with the high pill burden of traditional binders alone.

The safety profile is dominated by its local, mechanism-based effects. The FDA's Black Box Warning regarding the risk of serious dehydration in children is a critical and non-negotiable safety parameter that dictates its contraindication in the youngest patients. For adults, the successful clinical integration of Tenapanor is fundamentally dependent on the proactive management of its most common side effect, diarrhea. Patient education on the transient nature of this effect, along with clear guidance on when to suspend dosing and rehydrate, is essential for treatment adherence and success.

In conclusion, Tenapanor Hydrochloride is not merely an incremental addition to the therapeutic armamentarium. It is a mechanistically distinct agent that provides a valuable new tool for clinicians and a new source of hope for patients with IBS-C and hyperphosphatemia, particularly those who have been inadequately served by existing therapies. Its journey through clinical development and regulatory review highlights a sophisticated understanding of pharmacology, demonstrating how a targeted, localized mechanism can be harnessed to meet significant unmet medical needs, provided its predictable side effects are carefully and effectively managed.

Works cited

1. What is the therapeutic class of Tenapanor Hydrochloride?, accessed September 7, 2025, https://synapse.patsnap.com/article/what-is-the-therapeutic-class-of-tenapanor-hydrochloride
2. Tenapanor - Wikipedia, accessed September 7, 2025, https://en.wikipedia.org/wiki/Tenapanor
3. CENTER FOR DRUG EVALUATION AND ... - accessdata.fda.gov, accessed September 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211801Orig1s003.pdf
4. Xphozah (tenapanor) FDA Approval History - Drugs.com, accessed September 7, 2025, https://www.drugs.com/history/xphozah.html
5. Other Review(s) - accessdata.fda.gov, accessed September 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211801Orig1s000OtherR.pdf
6. IBSRELA® (tenapanor) Mechanism of Action | For US HCPs, accessed September 7, 2025, https://www.ibsrela-hcp.com/moa/
7. IBSRELA® (tenapanor) | IBS-C Treatment For Adult Patients, accessed September 7, 2025, https://www.ibsrela.com/
8. Xphozah: Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed September 7, 2025, https://www.drugs.com/xphozah.html
9. Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an ..., accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-receives-fda-approval-ibsrelar-tenapanor-nhe3-sodium
10. Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study - PMC - PubMed Central, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10695649/
11. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual ..., accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8259655/
12. Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/37853560/
13. Tenapanor Hydrochloride Monograph for Professionals - Drugs.com, accessed September 7, 2025, https://www.drugs.com/monograph/tenapanor-hydrochloride.html
14. Ibsrela (Tenapanor Tablets): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 7, 2025, https://www.rxlist.com/ibsrela-drug.htm
15. Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-topline-results-pivotal-phase-3
16. Tenapanor hydrochloride | DrugBank Online, accessed September 7, 2025, https://go.drugbank.com/salts/DBSALT002068
17. Tenapanor (Ibsrela) for the Treatment of Irritable Bowel Syndrome With Constipation - AAFP, accessed September 7, 2025, https://www.aafp.org/pubs/afp/issues/2022/0600/p656.html
18. Tenapanor (XPHOZAH®): First FDA Approved Phosphate Absorption, accessed September 7, 2025, https://www.pshp.org/news/680699/Tenapanor-XPHOZAH-First-FDA-Approved-Phosphate-Absorption-Inhibitor.htm
19. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate ..., accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8785778/
20. Ibsrela, Xphozah (tenapanor) dosing, indications, interactions, adverse effects, and more, accessed September 7, 2025, https://reference.medscape.com/drug/ibsrela-xphozah-tenapanor-1000311
21. Efficacy and Safety of Tenapanor in Hemodialysis Patients with Hyperphosphatemia: A Systematic Review and Meta-Analysis of Short-Term Randomized Controlled Trials - Karger Publishers, accessed September 7, 2025, https://karger.com/ajn/article/doi/10.1159/000546265/930214/Efficacy-and-safety-of-tenapanor-in-hemodialysis
22. Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-results-pivotal-phase-3-amplify-study
23. NCT04549597 | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia | ClinicalTrials.gov, accessed September 7, 2025, https://www.clinicaltrials.gov/study/NCT04549597
24. Tenapanor: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 7, 2025, https://go.drugbank.com/drugs/DB11761
25. Ibsrela Dosage Guide - Drugs.com, accessed September 7, 2025, https://www.drugs.com/dosage/ibsrela.html
26. Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy ..., accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10937073/
27. IBSRELA (tenapanor) tablets, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211801s003lbl.pdf
28. What clinical trials have been conducted for Tenapanor Hydrochloride? - Patsnap Synapse, accessed September 7, 2025, https://synapse.patsnap.com/article/what-clinical-trials-have-been-conducted-for-tenapanor-hydrochloride
29. Tenapanor hydrochloride - KEGG DRUG, accessed September 7, 2025, https://www.kegg.jp/entry/D11653
30. tenapanor - Drug Central, accessed September 7, 2025, https://drugcentral.org/drugcard/5349
31. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers - PubMed, accessed September 7, 2025, https://pubmed.ncbi.nlm.nih.gov/27368672/
32. Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-us-launch-ibsrelar-new-first-class-treatment
33. A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C | ClinicalTrials.gov, accessed September 7, 2025, https://www.clinicaltrials.gov/study/NCT02727751?term=AREA%5BBasicSearch%5D(TENAPANOR)&rank=5
34. Seeking Irritable Bowel Syndrome with Constipation (IBS-C) Patients for an Interventional Study - Rally with Mass General Brigham, accessed September 7, 2025, https://rally.massgeneralbrigham.org/study/tenapanor_ibsc
35. Treatment Response by Age - NET, accessed September 7, 2025, https://coursesv4bbs.blob.core.windows.net/nkf/content-item/9892fdff-6562-4ed5-8074-2284c360dc07/1191882ard_weiner_nfk2024_phreedom_comorbid_poster-42e3656f.pdf
36. Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology - BioSpace, accessed September 7, 2025, https://www.biospace.com/ardelyx-announces-peer-reviewed-publication-of-positive-phase-3-results-of-tenapanor-for-the-treatment-of-hyperphosphatemia-in-the-journal-of-the-american-society-of-nephrology
37. Ardelyx's experimental therapy tenapanor meets main goals of Phase III study for hyperphosphataemia - FirstWord Pharma, accessed September 7, 2025, https://firstwordpharma.com/story/4851499
38. Ardelyx's Tenapanor Hits the Mark in CKD Trial - BioSpace, accessed September 7, 2025, https://www.biospace.com/ardelyx-s-tenapanor-hits-the-mark-in-ckd-trial
39. Clinical Efficacy Data - XPHOZAH (tenapanor) Tablets, accessed September 7, 2025, https://xphozah-hcp.com/efficacy/
40. Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-presents-positive-data-further-supporting-efficacy-and-0
41. Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study, accessed September 7, 2025, https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2364824
42. Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-second-data-analysis-ongoing
43. Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study - Taylor & Francis Online, accessed September 7, 2025, https://www.tandfonline.com/doi/abs/10.1080/03007995.2024.2364824
44. Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZE study | Request PDF - ResearchGate, accessed September 7, 2025, https://www.researchgate.net/publication/382493975_Tenapanor_improves_long-term_control_of_high_phosphate_concentrations_in_the_blood_in_patients_receiving_maintenance_dialysis_a_plain_language_summary_of_the_NORMALIZE_study
45. Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis - PR Newswire, accessed September 7, 2025, https://www.prnewswire.com/news-releases/ardelyx-announces-positive-second-data-analysis-from-ongoing-normalize-phase-4-study-evaluating-tenapanor-in-ckd-patients-on-dialysis-301076616.html
46. Tenapanor Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 7, 2025, https://www.drugs.com/dosage/tenapanor.html
47. Getting Started with IBSRELA, accessed September 7, 2025, https://www.ibsrela.com/starting-ibsrela/
48. Summary Basis of Decision for Ibsrela - Drug and Health Products Portal, accessed September 7, 2025, https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD00492
49. IBSRELA (tenapanor) tablets, for oral use - accessdata.fda.gov, accessed September 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211801s014lbl.pdf
50. Tenapanor: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed September 7, 2025, https://www.rxlist.com/tenapanor/generic-drug.htm
51. Ibsrela Interactions: Other Medications, Alcohol, and More - Healthline, accessed September 7, 2025, https://www.healthline.com/health/drugs/ibsrela-interactions
52. Tenapanor Uses, Side Effects & Warnings - Drugs.com, accessed September 7, 2025, https://www.drugs.com/mtm/tenapanor.html
53. Ibsrela Disease Interactions - Drugs.com, accessed September 7, 2025, https://www.drugs.com/disease-interactions/tenapanor,ibsrela.html
54. Tenapanor (oral route) - Side effects & dosage - Mayo Clinic, accessed September 7, 2025, https://www.mayoclinic.org/drugs-supplements/tenapanor-oral-route/description/drg-20471207
55. Kyowa Kirin Announces Presentations of the Results of Phase 3 Studies of Tenapanor Hydrochloride (KHK7791) for Hemodialysis Pati, accessed September 7, 2025, https://www.kyowakirin.com/media_center/news_releases/2022/pdf/e20221020_01.pdf
56. XPHOZAH (tenapanor) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 7, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213931s000lbl.pdf
57. Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela - Benecard, accessed September 7, 2025, https://www.benecard.com/ardelyx-launches-irritable-bowel-syndrome-treatment-ibsrela/
58. Tenapanor and Alcohol/Food Interactions - Drugs.com, accessed September 7, 2025, https://www.drugs.com/food-interactions/tenapanor.html
59. Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders - PMC, accessed September 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5599948/
60. ir.ardelyx.com, accessed September 7, 2025, https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-receives-fda-approval-ibsrelar-tenapanor-nhe3-sodium#:~:text=On%20September%2012%2C%202019%20%2C%20Ardelyx,for%20hyperphosphatemia%20in%20certain%20territories.
61. Full article: Efficacy and safety of tenapanor in end-stage renal disease patients with hyperphosphatemia: a systematic review and meta-analysis, accessed September 7, 2025, https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2410389
62. Revestive | European Medicines Agency (EMA), accessed September 7, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/revestive
63. KEGG DRUG: New Drug Approvals in the USA, Europe and Japan, accessed September 7, 2025, https://www.genome.jp/kegg/drug/br08328.html
64. European Medicines Agency (EMA), accessed September 7, 2025, https://www.ema.europa.eu/en/medicines
65. National registers of authorised medicines | European Medicines Agency (EMA), accessed September 7, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
66. Authorisation of medicines | European Medicines Agency (EMA) - European Union, accessed September 7, 2025, https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines
67. Annexes – 2024 annual report of the European Medicines Agency, accessed September 7, 2025, https://www.ema.europa.eu/en/documents/annual-report/annexes-2024-annual-report-european-medicines-agency_en.pdf